Table 3

Demographic data and data related to serum concentration of ARI and DARI in women in different groups

CharacteristicARI
group
(n=70)
Comedication
group (n=123)
χ2P valueComedication
group
(n=123)
χ2P value
CLZ (n=30)RIP (n=29)QTP (n=32)OLZ (n=32)
Demographic
Age, yearsMean (SD)Mean (SD)tP valueMean (SD)Mean (SD)Mean (SD)Mean (SD)FP value
49.7 (18.5)43.0 (14.8)4.30<0.00151.1 (14.9)33.9 (10.6)43.4 (12.1)37.1 (15.5)18.54<0.001
Data related to serum concentration
ARI dose, mg/d19.3 (10.1)22.6 (11.0)–3.430.00120.3 (9.4)22.2 (16.7)24.5 (10.3)22.7 (9.0)4.950.001
Comedication dose, mg/dMedian
(IQR 25–75)
Median
(IQR 25–75)
χ2P valueMedian
(IQR25–IQR75)
Median
(IQR25–IQR75)
Median
(IQR25–IQR75)
Median
(IQR25–IQR75)
χ2P value
90.0 (87.0–100.0)2.0 (1.5–2.5)250.0 (200.0–300.0)10.0 (8.1–12.5)
ARI concentration, ng/ml210.1 (127.9–386.1)207.6 (121.2–340.5)−1.400.16200.5 (119.5–314.6)195.3 (110.8–380.3)218.6 (129.3–310.9)240.9 (125.3–392.4)4.760.31
DARI concentration, ng/ml96.7 (58.1–165.0)101.0 (69.1–177.2)−1.060.2999.3 (68.2–146.6)86.1 (51.3–162.3)111.4 (52.6–190.5)112.7 (65.8–198.3)4.040.40
ARI+DARI concentration, ng/ml337.2 (198.0–534.2)327.9 (199.5–512.0)−0.770.44302.8 (207.3–450.2)272.9 (170.7–518.0)334.7 (206.3–514.8)386.8 (214.0–557.7)3.610.46
ARI concentration/ARI dose, d/L12.7 (7.3–22.5)9.7 (6.2–15.1)−3.59<0.00110.1 (6.4–17.0)10.9 (4.2–20.4)9.5 (7.2–11.8)10.7 (5.5–19.8)15.910.003
DARI concentration/ARI dose, d/L5.6 (3.5–9.0)5.1 (3.3–7.7)−1.270.205.2 (3.6–8.6)4.8 (2.9–8.1)4.9 (3.2–6.5)5.3 (3.3–9.4)6.480.17
ARI+DARI concentration/ARI dose, d/L19.3 (11.1–30.7)15.1 (10.6–22.6)−3.100.00215.1 (11.7–23.2)14.2 (7.5–27.7)14.7 (11.1–18.1)15.9 (9.7–28.1)13.710.008
  • ARI, aripiprazole; CLZ, clozapine; DARI, dehydroaripiprazole; IQR, interquartile range; OLZ, olanzapine; QTP, quetiapine; RIP, risperidone; SD, standard deviation.